Nicotinamide for treating dyslipidemia

A technology for dyslipidemia and nicotinamide, which is applied in the direction of medical preparations containing active ingredients, metabolic diseases, drug combinations, etc., and can solve problems such as limited efficacy

Inactive Publication Date: 2020-03-06
SALMON PHARMA
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The present invention further addresses the problem of limited efficacy of available treatment options in terms of dyslipidemia and reduction of blood phosphate levels in patients with dyslipidemia and particularly CKD 3-5 due to changes in dietary phosphate intake and phosphate binding Treatment with antimicrobial agents is ineffective in reducing the phosphate burden in moderate CKD (Sprague, 2009(59), Oliveira, 2010(60))

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nicotinamide for treating dyslipidemia
  • Nicotinamide for treating dyslipidemia
  • Nicotinamide for treating dyslipidemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0157] Niacinamide improves Lp(a) levels in CKD patients.

[0158] To investigate the possible effect of nicotinamide on lowering serum Lp(a) levels, the inventors conducted preclinical studies in a transgenic mouse model. The biosynthesis of Lp(a) exists only in humans and Old World monkeys, which complicates the direct study of Lp(a) metabolism using animal models (Kostner, 2013(72)). Lp(a) consists of LDL covalently bound to Apo(a). Plasma Lp(a) levels in humans are highly correlated with Apo(a) synthesis. Since Lp(a) synthesis is limited to primates, a transgenic mouse model was adopted in which the entire Apo(a) gene including the promoter region was introduced into the mouse genome (Chennamsetty, 2012(31)). In transgenic Apo(a) mice (tg-Apo(a)), Apo(a) is mainly expressed in female mice. After these female mice were orally treated with food containing 1% niacin, plasma Apo(a) protein was reduced by 43%, and Apo(a) mRNA transcription in hepatocytes was reduced by 65% ​...

Embodiment 2

[0164] The combined therapeutic approach of nicotinamide and phosphate binders is particularly promising in the treatment of hyperphosphatemia in particular, because the pharmacological target of nicotinamide, the cotransporter NaPi2b, is strongly upregulated under treatment with phosphate binders . In this regard, it should also be noted again that phosphate binders, such as sevelamer and / or its derivatives, can negatively affect nicotinamide intake, which can be mitigated when co-administered with modified-release nicotinamide. Negative effects of phosphate binders.

[0165] There are two different mechanisms to explain intestinal phosphate absorption. Under conditions of normal dietary phosphate supply, passive paracellular diffusion accounts for the majority of phosphate uptake. In cases of dietary phosphate restriction, or treatment with phosphate binders to prevent intestinal phosphate absorption, the active cotransporter-driven process of absorption is enhanced, leadi...

Embodiment 3

[0182] Furthermore, most phosphate binders do not specifically react with phosphate, but also bind to other small polar molecules in the gut, potentially inhibiting their intestinal absorption (see e.g. Neradova, 2016(55)) . Indeed, when nicotinamide is combined with the phosphate binder sevelamer, with its known potential for broad gut interactions, nicotinamide was ineffective for the treatment of hyperphosphatemia ( See Olivero, 2006(43)). Sevelamer Carbonate The summary statement of the product characteristics of the drug is as follows: "Sevelamer is not absorbed and may affect the bioavailability of other drugs. When administered with any drug, if the decrease in bioavailability can have adverse effects on safety or efficacy." clinically significant effect, the drug should be administered at least 1 hour before or 3 hours after taking sevelamer, or physicians should consider monitoring blood levels." Due to the mode of action of phosphate binders, daily It must be tak...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical preparation comprising nicotinamide for use in a method of preventing and/or treating dyslipidemia, particularly resulting from renal failure, and a pharmaceutical preparation comprising nicotinamide for use in a method of preventing and/or treating elevated serum phosphate levels (hyperphosphatemia) and dyslipidemia, both particularly resulting from renal failure.

Description

[0001] The present invention relates to a pharmaceutical preparation comprising nicotinamide for use in a method of preventing and / or treating dyslipidemia, in particular caused by renal failure, and for preventing and / or treating elevated serum phosphate levels (hyperphosphatemia disease) and in the method of dyslipidemia, in particular both of which are caused by renal failure. Background technique [0002] Hyperphosphatemia, defined as supraphysiological levels of phosphate, is considered an independent risk factor for patients with chronic kidney disease (CKD) or chronic renal failure (CRF), according to DOPPS III [Young 2004(1) ,Tentori 2008(2)] Adequate treatment remains a challenge for approximately 50% to 70% of CKD patients who do not achieve recommended target phosphate levels [KDIGO Guidelines 2009(8); K / DOQI Clinical Practice Guidelines (clinical practice guidelines) 2003 (7)]. [0003] Kidney failure is the leading cause of hyperphosphatemia. Chronic renal failu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/455A61K45/06A61K33/06A61K33/10A61K33/244A61K33/26A61P3/06A61P3/12
CPCA61K45/06A61K31/455A61K33/06A61K31/785A61P13/12A61P3/12A61P3/06A61K2300/00A61K33/10A61K33/244A61K33/26A61K33/24
Inventor R·阿默尔
Owner SALMON PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap